Global Hypercholesterolemia Market 2014-2018

Global Hypercholesterolemia Market 2014-2018

Category : Healthcare
Published On : June  2014
Pages : 82

------------ Or -------------

About Hypercholesterolemia
Hypercholesterolemia is defined as a condition characterized by abnormally high levels of total cholesterol and LDL cholesterol in the blood. High cholesterol levels, in turn, can lead to cardiovascular diseases such as atherosclerosis and stroke. The normal physiological range of total blood cholesterol is 140-200 mg/dL. However, blood cholesterol consists of various individual components such as LDL cholesterol and HDL cholesterol. While LDL delivers cholesterol to the body, HDL removes cholesterol from cells by reverse cholesterol transport to the liver. Owing to their distinct roles, these components are separately taken into account to determine the dyslipidemic status of an individual. The inheritable form of hypercholesterolemia, characterized by elevated total cholesterol and LDL cholesterol levels, is known as familial hypercholesterolemia. When the condition is inherited due to the presence of one abnormal copy of the LDL receptor gene, it is known as heterozygous familial hypercholesterolemia. The presence of abnormal copies of both the LDL receptor alleles leads to homozygous familial hypercholesterolemia.
TechNavio's analysts forecast the Global Hypercholesterolemia market will grow at a CAGR of 3.81 percent over the period 2014-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Hypercholesterolemia market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various hypercholesterolemia management drugs that are available in the market which includes statins and other serum lipid lowering drugs. The report also presents the vendor landscape and a corresponding detailed analysis of the top five vendors in the Global Hypercholesterolemia market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
TechNavio's report, the Global Hypercholesterolemia Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hypercholesterolemia market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas 
• EMEA        
Key Vendors
• AbbVie Inc.
• Astrazeneca PLC 
• Merck & Co., Inc.
• Pfizer Inc.
Other Prominent Vendors
• Aegerion Pharmaceuticals Inc.
• Alnylam Pharmaceuticals Inc.
• Amgen Inc.
• AtheroNova Inc.
• Incorporated 
• Bristol-Myers Squibb Company
• Catabasis Pharmaceuticals Inc.
• Cerenis Therapeutics, SA
• CymaBay Therapeutics, Inc.
• Daiichi Sankyo Inc.
• Eli Lilly and Company
• Esperion Therapeutics Inc.
• Glaxosmithkline plc
• Kadmon Pharmaceuticals LLC
• Kowa Pharmaceuticals America Inc.
• Laboratoires SMB S.A.
• Madrigal Pharmaceuticals Inc.
• Novartis AG
• Regeneron Pharmaceuticals Inc.
• REGENX BioSciences, LLC
• Santaris Pharma A/S
• Serometrix LLC
• Shionogi Pharma Inc.
• Spherix Incorporated
• Sun Pharma USA 
• Tekmira Pharmaceuticals Corp.
Key Market Driver
• Increase in the Incidence and Prevalence of Cardiovascular Diseases.
• For a full, detailed list, view our report.
Key Market Challenge
• Increase in Generic Erosion.
• For a full, detailed list, view our report.
Key Market Trend
• Fierce Market Competition.
• For a full, detailed list, view our report.
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.




01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis 

07. Clinical Pipeline Portfolio

08. Market Segmentation by Type of Disease

09. Market Segmentation by MOA

10. Global Statins Market

11. Geographical Segmentation

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

19.1 Competitive Scenario

19.1.1 Key News

19.1.2 Mergers and Acquisitions

19.2 Market Share Analysis 2013

19.3 Other Prominent Vendors

19.4 Future Players Expected to Tap the Market

20. Key Vendor Analysis

List of Exhibits

Exhibit 1: Market Research Methodology

Exhibit 2: Global Hypercholesterolemia Market 2013-2018 (US$ billion)

Exhibit 3: Classification of Hyperlipidemia

Exhibit 4: Market Segmentation of Hypercholesterolemia Drugs by MOA

Exhibit 5: Market Share Segmentation on the Basis of MOA 2013 

Exhibit 6: Number of Prescriptions for Cholesterol Lowering Classes in 2012 (in percent)

Exhibit 7: Number of Prescriptions for Statins in US (in 2012)

Exhibit 8: Number of Prescriptions for Non-Statins in US by (in 2012)

Exhibit 9: Global Statins Market 2013-2018 (US$ billion)

Exhibit 10: Global Hypercholesterolemia Market by Geographical Segmentation 2013


Enquiry Before Buy